De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PDS Biotechnology Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat PDS Biotechnology de winst en omzet met respectievelijk 5.3% en 76.6% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 13.8% per jaar.

Belangrijke informatie

5.3%

Groei van de winst

13.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.6%
Inkomstengroei	76.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	07 Oct 2024

Recente toekomstige groei-updates

Recent updates

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Jan 13

PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101

Feb 03

PDS Biotechnology gives new CFO ~202K stock grant

Jan 06

Winst- en omzetgroeiprognoses

NasdaqCM:PDSB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	8	-56	-56	-54	3
12/31/2025	0	-58	-50	-51	5
12/31/2024	N/A	-42	-38	-41	5
6/30/2024	N/A	-41	-34	-34	N/A
3/31/2024	N/A	-44	-30	-30	N/A
12/31/2023	N/A	-43	-34	-34	N/A
9/30/2023	N/A	-51	-33	-33	N/A
6/30/2023	N/A	-48	-31	-31	N/A
3/31/2023	N/A	-42	-33	-33	N/A
12/31/2022	N/A	-41	-26	-26	N/A
9/30/2022	N/A	-28	-23	-23	N/A
6/30/2022	N/A	-28	-22	-22	N/A
3/31/2022	N/A	-22	-15	-15	N/A
12/31/2021	N/A	-17	-12	-12	N/A
9/30/2021	N/A	-15	-13	-13	N/A
6/30/2021	N/A	-12	-9	-9	N/A
3/31/2021	N/A	-14	-14	-14	N/A
12/31/2020	N/A	-15	-13	-13	N/A
9/30/2020	N/A	-15	-14	-14	N/A
6/30/2020	N/A	-17	-17	-17	N/A
3/31/2020	N/A	-18	-18	-18	N/A
12/31/2019	N/A	-7	-18	-18	N/A
9/30/2019	N/A	-5	-13	-13	N/A
6/30/2019	N/A	0	-9	-9	N/A
3/31/2019	N/A	4	-5	-5	N/A
12/31/2018	N/A	-4	-2	-2	N/A
9/30/2018	N/A	-2	-2	-2	N/A
12/31/2017	N/A	-3	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PDSB de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PDSB de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PDSB de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PDSB ( 76.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van PDSB ( 76.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PDSB naar verwachting over 3 jaar hoog zal zijn

PDS Biotechnology Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 8.4% to US$17.67

Price target increased by 7.9% to US$19.43

Price target increased to US$18.25

Price target increased to US$18.00

Price target decreased to US$17.71

Price target increased to US$20.50

Recent updates

PDS Biotechnology Corporation Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

PDS Biotechnology Corporation Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

New major risk - Revenue and earnings growth

PDS Biotechnology Corporation to Report Q2, 2024 Results on Aug 13, 2024

Pds Biotech Aligns with Fda on Phase 3 Trial in Hpv16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

PDS Biotechnology Corporation(NasdaqCM:PDSB) dropped from Russell Small Cap Completeness Index

New minor risk - Market cap size

PDS Biotech Provides Data Update from Ongoing Versatile-002 Phase 2 Clinical Trial in Head and Neck Cancer

PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2024 Results on May 15, 2024

PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer

PDS Biotechnology Corporation, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

New minor risk - Shareholder dilution

PDS Biotechnology Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024

PDS Biotechnology Corporation Announces Publication of Preclinical Research

PDS Biotechnology Corporation Announces Executive Changes

PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk

Pds Biotech Announces CFO Changes

Price target decreased by 8.4% to US$17.67

PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients

PDS Biotechnology Corporation to Report Q3, 2023 Results on Nov 14, 2023

PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO

PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

New major risk - Financial position

PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial

PDS Biotechnology Corporation to Report Q2, 2023 Results on Aug 14, 2023

PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023

PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of Versamune®? and PDS0301

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the Versatile-002 Trial Evaluating Pds0101 and Keytruda in Head and Neck Cancer

PDS Biotechnology Corporation, Annual General Meeting, Jul 14, 2023

PDS Biotechnology Corporation Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with Keytruda (Pembrolizumab) for Head and Neck Cancer Patients

Pds Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of Versatile-002 Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

PDS Biotechnology Corporation to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

Price target increased by 7.9% to US$19.43

PDS Biotechnology Corporation Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune

PDS Biotechnology Corporation Announces Preclinical Studies Involving Infectimune

PDS Biotechnology Corporation Announces Abstract Accepted for Presentation At ESMO Targeted Anticancer Therapies Congress

PDS Biotechnology Corporation Reports Median Overall Survival of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 Months

Price target increased to US$18.25

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer

President exercised options and sold US$562k worth of stock

Price target increased to US$18.00

PDS Biotechnology Corporation Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from Immunocerv Phase 2 Clinical Trial

PDS Biotechnology Corporation Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

PDS Biotechnology Corporation to Report Q3, 2022 Results on Nov 14, 2022

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

PDS Biotechnology Corporation Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

Price target decreased to US$17.71

PDS Biotechnology Corporation Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA(R)

PDS Biotech jumps 13% as FDA clears further development of lead asset

PDS Biotechnology Corporation Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

PDS Biotechnology files for $150 mixed shelf offering

PDS Biotech Independent Data Monitoring Committee Recommends Versatile-002 Trial Continuation Without Modifications

PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

PDS Biotechnology Corporation to Report Q2, 2022 Results on Aug 08, 2022

PDS Biotechnology Corporation Announces Presentation of Universal Flu Vaccine Preclinical Data At American Society of Virology Meeting

PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business

PDS Biotechnology Corporation Appoints Spencer Brown as Senior Vice President, General Counsel

U.S. Food and Drug Administration Grants PDS Biotechnology Fast Track Designation for Lead Candidate Pds0101

PDS Biotechnology Corporation Announces Expansion of Its VERSATILE-002 Clinical Trial into Europe

PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data

PDS Biotechnology Corporation Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer At Asco 2022

PDS Biotechnology Corporation Appoints Sanjay Zaveri as Senior Vice President, Business Development

PDS Biotechnology Corporation, Annual General Meeting, Jun 15, 2022

PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$20.50